14.04.2020 • NewsDede WillamsNovartisBlackstone

Blackstone Invests $ 2 Billion in Biotech Alnylam

Blackstone Invests $ 2 Billion in Biotech Alnylam (c) Alnylam
Blackstone Invests $ 2 Billion in Biotech Alnylam (c) Alnylam

Through a combination of equity and debt, private equity giant Blackstone will invest up to $2 billion in Cambridge, Massachusetts-based US biotech Alnylam Pharmaceuticals. The  company founded in 2002 specializes in RNA interference, which intercepts disease-causing proteins.

The multi-component deal gives the publicly traded biotech needed resources to move through the costly phase of bringing late-stage drugs to market, analysts commented.

With a cash injection of $1 billion, Blackstone is secuing rights to 50% of the royalties and commercial milestones for inclisiran, an investigational RNAi therapeutic currently under review by both the US Food and Drug Administration (FDA)and the European Medicines Agency (EMA).

Inclisiran is being recommended for treatment of atherosclerotic heart disease and hypercholesterolemia, a genetic disorder that causes very high cholesterol. Phase 3 clinical trials are said to have shown it can reduce low-density lipoprotein (LDL) or "bad" cholesterol with an acceptable safety profile

The drug is being developed in partnership with Switzerland’s Novartis, which picked it up in its $9.7 billion takeover of The Medicines Company, where it was under license.

As part of the deal, Blackstone is also buying $100 million in Alnylam shares, and the investor’s Life Sciences unit has agreed to invest up to $150 million in the development of two other Alnylam drugs.  Cardiometabolic vutrisiran is being investigated for ATTR amyloidosis and ALN-AGT is aimed at treating hypertension.

The private equity group headed by Steven Schwarzman is also providing Alnylam with a loan worth up to $750 million, which US business newspaper Wall Street Journal called “noteworthy both for its size and because biotech companies with unproven drugs and uncertain cash flow are often considered too risky for many lenders.”

Senior managing director at GSO, Brad Marshall, noted, however, that Alnylam is unique because it has two drugs already on the market and a manufacturing facility, in addition to the new cholesterol drug.

In February 2019, Blackstone Life Sciences invested $250 million in a joint venture with Novartis to develop drugs to treat blood clots. In November 2019, it contributed $400 million to a joint venture with Ferring Pharmaceuticals to develop and market a gene therapy to treat bladder cancer.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.